Drug stocks give FTSE a shot in the arm

clock

The FTSE 100 is off to a good start to the week with gains of 12.5 points, or 0.23%, to 5,544.1, with drug stocks leading the advance in response to news a US judge has upheld key patents on Pfizer's Lipitor cholesterol drug.

AstraZeneca, which makes the Crestor cholesterol treatment, has risen 65p, or 2.37%, to 2,812p, while GlaxoSmithKline has gained 30p, or 2.05%, to 1,490p, as the US ruling handed Pfizer patent protection on the world's best-selling drug until June 2011, dealing a blow to generic drug makers. Elsewhere, Kazakhstan miner Kazakhmys, entering the FTSE 100 for the first time since its October flotation, has fallen 8p, or 1.16%, to 680p, after it said copper cathode production in the first nine months of the year was in line with expectations. Housebuilder Persimmon, which is also making its ...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Investment

Advisers look to capital accumulation in Q2 2025

Advisers look to capital accumulation in Q2 2025

Interest in inflation protection nudges up

Jen Frost
clock 18 July 2025 • 3 min read
For companies – and their investors – management matters

For companies – and their investors – management matters

'Management, whatever the setting, really is a difference-maker'

Gabriel Sacks
clock 17 July 2025 • 4 min read
'No difference in my view': Reeves LTAF-ISA decree not enough to make platforms offer them

'No difference in my view': Reeves LTAF-ISA decree not enough to make platforms offer them

Retail platforms await further rule change details

Eve Maddock-Jones
clock 16 July 2025 • 4 min read